Skip to main content
SpringerLink
Log in

Increased HCC risk in cirrhosis patients treated with DAAs?

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Nahon P, et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology : [67 pages], 18 Jul 2018. Available from: URL: http://dx.doi.org/10.1053/j.gastro.2018.07.015

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Increased HCC risk in cirrhosis patients treated with DAAs?. Reactions Weekly 1713, 10 (2018). https://doi.org/10.1007/s40278-018-49844-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-49844-8

Search

Navigation